Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC

Liver Int. 2023 Jan;43(1):258-259. doi: 10.1111/liv.15482. Epub 2022 Dec 5.

Authors

Ariel Jaffe^{1

2}, Tamar H Taddei¹, Edoardo G Giannini³, Ysabel C Ilagan-Ying¹, Massimo Colombo⁴, Mario Strazzabosco^{1

2}

Affiliations

¹ Liver Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
² Smilow Cancer Hospital and Liver Cancer Program, New Haven, Connecticut, USA.
³ Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁴ Liver Center, San Raffaele Hospital, Milan, Italy.

PMID: 36426717
DOI: 10.1111/liv.15482

No abstract available

Publication types

Letter
Comment

MeSH terms

Artificial Intelligence
Biomarkers, Tumor
Carcinoma, Hepatocellular* / therapy
Humans
Liver Neoplasms* / therapy
Prognosis

Substances

Biomarkers, Tumor